Bisphosphonate sequestering agents. Synthesis and preliminary evaluation for in vitro and in vivo uranium(VI) chelation
摘要:
A library of bisphosphonate-based ligands was prepared using solution-phase parallel synthesis and tested for its uranium-binding properties. With the help of a screening method, based on a chromophoric complex displacement procedure, 23 dipodal and tripodal chelates bearing bisphosphonate chelating functions were found to display very high affinity for the uranyl ion and were selected for evaluation of their in vivo uranyl-removal efficacy. Among them, 11 ligands induced a huge modification of the uranyl biodistribution by deviating the metal from kidney and bones to liver. Among the other ligands, the most potent was the dipodal bisphosphonate 3C which reduced the retention of uranyl and increased its excretion by around 10% of the injected metal. (C) 2008 Elsevier Masson SAS. All rights reserved.
金属药物为各种形式的人类癌症提供重要的一线治疗。为了克服化疗耐药性并扩大治疗可能性,具有改进或替代作用模式的新药物受到高度追捧。在这里,我们提出了一种用于开发 DNA 损伤金属药物的点击化学策略。该方法涉及开发一系列多胺配体,其中选择三种伯、仲或叔炔胺,并使用铜催化的叠氮-炔环加成反应“点击”至1,3,5-叠氮均三甲苯核心,产生我们称之为“Tri-Click”(TC) 系列的一系列化合物。从分离的文库中,出现了一种优势配体 (TC1),它是一种高亲和力的铜 (II) 结合剂,具有有效的 DNA 识别和破坏特性。使用一系列体外生物物理和分子技术(包括自由基清除剂、自旋捕获抗氧化剂和碱基切除修复 (BER) 酶),阐明了铜结合 TC1 的氧化 DNA 损伤机制。然后将该活性与暴露于 Cu(II)-TC1 的外周血单核细胞获得的细胞内结果进行比较,其中使用 BER 酶和荧光修饰的 dNTP 能够对复合物产生的基因组
[EN] METALLODRUG THERAPEUTIC COMPOUNDS AND PRODRUGS OF METALLODRUG THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES À BASE DE MÉTALLO-MÉDICAMENTS ET PROMÉDICAMENTS DE COMPOSÉS THÉRAPEUTIQUES À BASE DE MÉTALLO-MÉDICAMENTS
申请人:[en]DUBLIN CITY UNIVERSITY
公开号:WO2023031375A1
公开(公告)日:2023-03-09
Disclosed herein are compounds of formula (I). In particular, the compounds are metallodrug therapeutic compounds or prodrugs of metallodrug therapeutic compounds. The metallodrug therapeutic compounds and prodrugs of metallodrug therapeutic compounds are for use in therapy, for example in the treatment and detection of cancer.